A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: The Lipid Treatment Assessment Project 2
Open accessAbstract
Objective This study evaluated the success in attaining non-HDL-cholesterol (non-HDL-C) goals in the multinational L-TAP 2 study.Methods 9955 patients ≥20 years of age with dyslipidemia on stable lipid-lowering therapy were enrolled from nine countries.Results Success rates for non-HDL-C goals were 86% in low, 70% in moderate, and 52% in high-risk patients (63% overall). In patients with triglycerides of >200 mg/dL success rates for non-HDL-C goals were 35% vs. 69% in those with ≤200 mg/dL (p < 0.0001). Among patients attaining their LDL-C goal, 18% did not attain their non-HDL-C goal. In those with coronary disease and at least two risk factors, only 34% and 30% attained respectively their non-HDL-C and LDL-C goals. Rates of failure in attaining both LDL-C and non-HDL-C goals were highest in Latin America.Conclusions Non-HDL-C goal attainment lagged behind LDL-C goal attainment; this gap was greatest in higher-risk patients.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The majority of patients with dyslipidaemia do not attain adequate LDL-C levels by existing lifestyle modifications and pharmacological treatment strategies.
“Despite the widespread availability of low-cost statins, the majority of patients with dyslipidaemia do not attain adequate LDL-C levels by existing lifestyle modifications and pharmacological treatment strategies [7–11].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [8]
The Results report that 73% of the 9,955 patients attained their LDL-C goals, contrary to the claim that a majority did not. The paper reports lower attainment in some high-risk subgroups, but not in the overall study population; it also does not evaluate lifestyle modifications as a treatment strategy. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredDespite treatment with statins, patients with elevated low-density lipoprotein cholesterol and triglycerides remain at increased risk for adverse cardiovascular events.
“Despite treatment with statins, patients with elevated low-density lipoprotein cholesterol (LDL-C) and triglycerides remain at increased risk for adverse cardiovascular events.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [8]
The Clinical implications section says persistently elevated non-HDL-C is associated with a greater chance of disease recurrence even after LDL-C reduction. The Results section finds that patients with higher triglycerides less often attained LDL-C and non-HDL-C goals. But the paper does not establish increased cardiovascular-event risk specifically for statin-treated patients with both elevated LDL-C and triglycerides; its risk statement concerns non-HDL-C. (LLM, conf=0.83)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944 · see citing works
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860 · see citing works
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198 · see citing works
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550 · see citing works
Global Burden of Cardiovascular Diseases
Yusuf, S., Reddy, S., Ôunpuu, S., & Anand, S. S. (2001) · Circulation · doi:10.1161/hc4601.099487 · Cited by 2,979 · see citing works
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731 · see citing works
De Backer, G. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00347-6 · Cited by 2,251 · see citing works
Genest, J. J., McPherson, R., Frohlich, J. J., Anderson, T. J., Campbell, N. R. C., Carpentier, A. C., Couture, P., Dufour, R., Fodor, G. J., Francis, G. A., et al. (2009) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(09)70715-9 · Cited by 758 · see citing works
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706 · see citing works
Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment
Kastelein, J. J. P., van der Steeg, W. A., Holme, I., Gaffney, M., Cater, N. B., Barter, P., Deedwania, P., Olsson, A. G., Boekholdt, S. M., Demicco, D. A., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.713438 · Cited by 478 · see citing works
Robinson, J. G., Wang, S., Smith, B. J., & Jacobson, T. A. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.024 · Cited by 368 · see citing works
Genest, J. J., Frohlich, J. J., Fodor, G. J., & McPherson, R. (2003) · PubMed Central · Cited by 345 · see citing works
Lipid Treatment Assessment Project 2
Waters, D. D., Brotons, C., Chiang, C.-W., Ferrières, J., Foody, J. M., Jukema, J. W., Santos, R. D., Verdejo, J., Messig, M., McPherson, R., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.838466 · Cited by 305 · see citing works
Self-citationDavidson, M. H., Maki, K. C., Pearson, T. A., Pasternak, R. C., Deedwania, P. C., McKenney, J. M., Fonarow, G. C., Maron, D. J., Ansell, B. J., Clark, L. T., et al. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.04.019 · Cited by 270 · see citing works
The importance of non–HDL cholesterol reporting in lipid management
Blaha, M. J., Blumenthal, R. S., Brinton, E. A., & Jacobson, T. A. (2008) · Journal of clinical lipidology · doi:10.1016/j.jacl.2008.06.013 · Cited by 193 · see citing works
Virani, S. S., Woodard, L., Landrum, C. R., Pietz, K., Wang, D., Ballantyne, C. M., & Petersen, L. A. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.03.023 · Cited by 46 · see citing works
Flagged first, then by citations
2 of the 19 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- [10]10. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601e10.
Cited by
Sorted by citations
Robinson, J. G., Nedergaard, B. S., Rogers, W. J., Fialkow, J., Neutel, J. M., Ramstad, D., Somaratne, R., Legg, J. C., Nelson, P., Scott, R., et al. (2014) · JAMA · doi:10.1001/jama.2014.4030 · Cited by 496 · see citing works
Hirayama, A., Honarpour, N., Yoshida, M., Yamashita, S., Huang, F., Wasserman, S. M., & Teramoto, T. (2014) · Circulation Journal · doi:10.1253/circj.cj-14-0130 · Cited by 116 · see citing works
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109 · see citing works
Rao, A. S., Lindholm, D., Rivas, M. A., Knowles, J. W., Montgomery, S. B., & Ingelsson, E. (2018) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.118.002162 · Cited by 60 · see citing works
Bruckert, É., Parhofer, K. G., González‐Juanatey, J. R., Nordestgaard, B. G., Arca, M., Giovas, P. P., & Ray, K. K. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01285-2 · Cited by 59 · see citing works
New treatment options for lipid-lowering therapy in subjects with type 2 diabetes
Scicali, R., Pino, A. D., Ferrara, V., Urbano, F., Piro, S., Rabuazzo, A. M., & Purrello, F. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-1089-4 · Cited by 44 · see citing works
Ewang-Emukowhate, M., & Wierzbicki, A. S. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413492906 · Cited by 39 · see citing works
Toth, P. P., Jones, S. R., Monsalvo, M. L., Elliott‐Davey, M., López, J. A. G., & Banach, M. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014129 · Cited by 36 · see citing works
Barkas, F., Liberopoulos, E. N., Kostapanos, M. S., Liamis, G. L., Tziallas, D., & Elisaf, M. (2014) · Angiology · doi:10.1177/0003319714535073 · Cited by 32 · see citing works
Recaticimab as Add-On Therapy to Statins for Nonfamilial Hypercholesterolemia
Sun, Y., Lv, Q., Guo, Y., Wang, Z., Huang, R., Gao, X., Han, Y., Yao, Z., Zheng, M., Luo, S., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.09.012 · Cited by 32 · see citing works
Le, N., Tomassini, J. E., Tershakovec, A. M., Neff, D., & Wilson, P. W. F. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.114.001675 · Cited by 28 · see citing works
Barkas, F., Milionis, H. J., Kostapanos, M. S., Mikhailidis, D. P., Elisaf, M., & Liberopoulos, E. N. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.982751 · Cited by 27 · see citing works
Gulizia, M. M., Colivicchi, F., Ricciardi, G., Giampaoli, S., Maggioni, A. P., Averna, M. R., Graziani, M. S., Ceriotti, F., Mugelli, A., Rossi, F., et al. (2017) · European Heart Journal Supplements · doi:10.1093/eurheartj/sux029 · Cited by 27 · see citing works
New therapies to reduce low-density lipoprotein cholesterol
Wierzbicki, A. S., Viljoen, A., Hardman, T. C., & Mikhailidis, D. P. (2013) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283605fa2 · Cited by 24 · see citing works
Marrett, E., Zhao, C., Zhang, N. J., Zhang, Q., Ramey, D. R., Tomassini, J. E., Tershakovec, A. M., & Neff, D. (2014) · Vascular Health and Risk Management · doi:10.2147/vhrm.s54886 · Cited by 17 · see citing works
Henry, R. R., Müller‐Wieland, D., Taub, P. R., Bujas‐Bobanovic, M., Louie, M. J., Letierce, A., & Ginsberg, H. N. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13273 · Cited by 16 · see citing works
Statin Combination Therapy and Cardiovascular Risk Reduction
Toth, P. P., Farnier, M., Tomassini, J. E., Foody, J. M., & Tershakovec, A. M. (2016) · Future Cardiology · doi:10.2217/fca-2015-0011 · Cited by 16 · see citing works
Self-citationRobinson, J. G., Rogers, W. J., Nedergaard, B. S., Fialkow, J. A., Neutel, J. M., Ramstad, D., Somaratne, R. M., Legg, J. C., Nelson, P., Scott, R. C., et al. (2014) · Clinical Cardiology · doi:10.1002/clc.22252 · Cited by 15 · see citing works
The Need for Combination Drug Therapies in Patients with Complex Dyslipidemia
Barnett, J. R., Viljoen, A., & Wierzbicki, A. S. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0391-1 · Cited by 15 · see citing works
Angelini, S., Rosticci, M., Massimo, G., Musti, M. A., Ravegnini, G., Consolini, N., Sammarini, G., D’Addato, S., Rizzoli, E., Botbayev, D. M., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010049 · Cited by 13 · see citing works
Xanthopoulou, I., Davlouros, P. A., Siahos, S., Perperis, A., Zaharioglou, E., & Alexopoulos, D. K. (2013) · Lipids in Health and Disease · doi:10.1186/1476-511x-12-170 · Cited by 13 · see citing works
Qiu, R., Luo, G., Li, X., Zheng, F., Li, H., Zhang, J., You, Q., & Xiang, H. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.07.026 · Cited by 12 · see citing works
Zhang, C., Huang, Z., Jing, H., Fu, W., Yuan, M., Xia, W., Cai, L., Gan, X., Chen, Y., Zou, M., et al. (2017) · Theranostics · doi:10.7150/thno.18415 · Cited by 11 · see citing works
El‐Tamalawy, M. M., Ibrahim, O. M., Hassan, T. M., & El‐Barbari, A. A. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.976 · Cited by 10 · see citing works
Cuevas, A. M., Arteaga, A., & Rigotti, A. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0400-x · Cited by 9 · see citing works
Efficacy and safety of ezetimibe plus atorvastatin therapy
Foody, J. M., Toth, P. P., Tershakovec, A. M., Musliner, T., Tomassini, J. E., Lowe, R. S., Neff, D., & Davis, H. R. (2014) · Clinical Lipidology · doi:10.2217/clp.14.36 · Cited by 8 · see citing works
Self-citationAchievement of LDL Cholesterol Goal and Adherence to Statin by Diabetes Patients in Kelantan
Yudin, Z. M., Yaacob, L. H., Hassan, N. B., Ismail, S. B., Draman, N., & Yusoff, S. S. M. (2017) · Malaysian Journal of Medical Sciences · doi:10.21315/mjms2017.24.3.6 · Cited by 7 · see citing works
Rioux-Labrecque, V., Cossette, M., Rufiange, M., Bilodeau, D., Guertin, M., & Tardif, J. (2023) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.04.012 · Cited by 6 · see citing works
Update on management of paediatric dyslipidaemia
Bansal, N., Kumar, S., & Brar, P. C. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000794 · Cited by 4 · see citing works
Filho, A. C. V. A., Guedes, M. I. F., Duarte, L. S. F., Neto, A. B. M. L., Cameron, L. C., Bassini, A., Vieira, Í. G. P., de Melo, T. S., de Almeida, L. M., & de Queiroz, M. G. R. (2014) · International Journal of Pharmacy and Pharmaceutical Sciences · Cited by 5 · see citing works
Achievement of LDL Cholesterol Goal and Adherence to Statin by Diabetes Patients in Kelantan
Yudin, Z. M., Yaacob, L. H., Hassan, N. B., Ismail, S. B., Draman, N., & Yusoff, S. S. M. (2017) · PubMed Central · doi:10.21315/mjms2016.24.3.6 · Cited by 5 · see citing works
PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?
Yang, E. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.263 · Cited by 4 · see citing works
Genomics and Pharmacogenomics of Lipid-Lowering Therapies
Docherty, K. F., & Padmanabhan, S. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386882-4.00031-1 · Cited by 3 · see citing works
Dose wisely! How lipid-lowering undertreatment can lead to overtreatment
Masana, L., & van Lennep, J. E. R. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.10.014 · Cited by 3 · see citing works
Echeverría, G., Catalina Dussaillant, K., Villarroel, L. A., & Rigotti, A. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.11.008 · Cited by 2 · see citing works
The Study of Non-HDL Cholesterol Levels Compared to LDL Cholesterol Levels in Diabetics
Chaitanya Krishna, N. (2017) · Journal of Medical Science And clinical Research · doi:10.18535/jmscr/v5i3.72 · Cited by 1 · see citing works
Local effects of Linoorbitides and enterolactone On intestinal epithelial functions
Almousa, A. A. (2017) · University Library - University of Saskatchewan (University of Saskatchewan) · Cited by 1 · see citing works
Novel therapies for dyslipidemia
Wierzbicki, A. S. (2013) · doi:10.2217/fmeb2013.13.9
Arif, A., Karungi, I., Stevens, C. A. T., Elshorbagy, A. K., & Ray, K. K. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120644
- Authors
- Santos, R. D., Waters, D. D., Tarasenko, L., Messig, M., Jukema, J. W., Chiang, C.-W., Ferrieres, J., & Foody, J. M.
- Affiliations
- Universidade de São Paulo (BR)
- San Francisco General Hospital (US)
- Pfizer (United States) (US)
- Leiden University Medical Center (NL)
- Cathay General Hospital (TW)
- Brigham and Women's Hospital (US)
- Corresponding author
- Santos, Raul D.
- Venue
- Atherosclerosis
- Publisher
- Elsevier BV
- Published
- 2012-09
- Volume
- 224
- Issue
- 1
- Pages
- 150-153
- ISSN
- 0021-9150 (ISSN-L)
- OpenAlex
- W2078726774
- Semantic Scholar
- 292ad28eb15d83dccb919476408eb3c6a6862f85
- Cited by
- 39
- References
- 19
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 2 · 2022: 1 · 2020: 2 · 2018: 3 · 2017: 9 · 2016: 2 · 2015: 3 · 2014: 10 · 2013: 5
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Atherosclerosis (publishedVersion)
- PubMed (publishedVersion)
- Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- non-HDL cholesterol, LDL cholesterol, dyslipidemia, lipid-lowering therapy, triglycerides, coronary artery disease, cardiovascular risk factors, Latin America
- MeSH terms
- Adult, Aged, Hypolipidemic Agents, Canada, Coronary Disease, Europe, Female, Humans, Latin America, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Risk Factors, Triglycerides, United States, Treatment Outcome, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
